S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Korro Bio (KRRO) Competitors

$49.30
+1.00 (+2.07%)
(As of 03/1/2024 ET)

KRRO vs. TCRT, EFTR, LSDI, VYNE, MRKR, HUGE, YS, SLS, CPIX, and BFRG

Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Alaunos Therapeutics (TCRT), eFFECTOR Therapeutics (EFTR), Lucy Scientific Discovery (LSDI), VYNE Therapeutics (VYNE), Marker Therapeutics (MRKR), FSD Pharma (HUGE), YS Biopharma (YS), SELLAS Life Sciences Group (SLS), Cumberland Pharmaceuticals (CPIX), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical preparations" industry.

Korro Bio vs.

Alaunos Therapeutics (NASDAQ:TCRT) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Alaunos Therapeutics currently has a consensus target price of $45.00, indicating a potential upside of 1,913.42%. Korro Bio has a consensus target price of $117.50, indicating a potential upside of 138.34%. Given Korro Bio's higher probable upside, equities research analysts clearly believe Alaunos Therapeutics is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Korro Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alaunos Therapeutics has higher earnings, but lower revenue than Korro Bio. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos Therapeutics$2.92M12.28-$37.73M-$2.40-0.93
Korro Bio$14.07M2.59-$81.58M-$94.50-0.52

Alaunos Therapeutics received 2 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.

CompanyUnderperformOutperform
Alaunos TherapeuticsOutperform Votes
7
58.33%
Underperform Votes
5
41.67%
Korro BioOutperform Votes
5
100.00%
Underperform Votes
No Votes

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 6.2% of Alaunos Therapeutics shares are held by insiders. Comparatively, 16.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alaunos Therapeutics' return on equity of -115.97% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -140.74% -90.61%
Korro Bio N/A -115.97%-68.09%

Alaunos Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500.

In the previous week, Korro Bio had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for Korro Bio and 1 mentions for Alaunos Therapeutics. Korro Bio's average media sentiment score of 1.87 beat Alaunos Therapeutics' score of 0.77 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Alaunos Therapeutics Very Positive
Korro Bio Positive

Summary

Korro Bio beats Alaunos Therapeutics on 10 of the 17 factors compared between the two stocks.


Get Korro Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRRO vs. The Competition

MetricKorro BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$36.48M$6.93B$5.05B$7.61B
Dividend YieldN/A2.81%2.81%3.87%
P/E Ratio-0.5219.08268.4718.95
Price / Sales2.59216.093,019.5373.94
Price / CashN/A19.0798.1954.91
Price / Book0.504.944.594.72
Net Income-$81.58M$162.80M$114.93M$211.49M
7 Day Performance-1.38%7.32%5.64%3.36%
1 Month Performance-7.59%15.72%11.13%6.69%
1 Year PerformanceN/A6.91%13.96%8.87%

Korro Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
2.026 of 5 stars
$2.16
-3.1%
$45.00
+1,983.3%
-73.0%$34.67M$2.92M-0.9034Upcoming Earnings
Positive News
EFTR
eFFECTOR Therapeutics
2.5085 of 5 stars
$13.14
+13.1%
$99.50
+657.2%
+26.4%$33.90M$3.55M-0.6915News Coverage
High Trading Volume
LSDI
Lucy Scientific Discovery
0 of 5 stars
$2.03
-3.8%
N/A-89.8%$35.83M$10,000.00-2.902Stock Split
Short Interest ↓
VYNE
VYNE Therapeutics
3.205 of 5 stars
$2.37
+0.9%
$7.38
+211.2%
-25.5%$33.09M$480,000.00-0.2312Analyst Report
Short Interest ↓
News Coverage
MRKR
Marker Therapeutics
0 of 5 stars
$3.70
-2.1%
N/A+80.0%$32.89M$5.50M0.0067Gap Down
HUGE
FSD Pharma
0 of 5 stars
$0.94
-2.1%
N/A-46.7%$37.10MN/A-1.6017Gap Up
High Trading Volume
YS
YS Biopharma
2.5857 of 5 stars
$0.40
+2.6%
$5.25
+1,212.8%
N/A$37.22M$100M0.00754Short Interest ↑
Gap Up
SLS
SELLAS Life Sciences Group
1.2789 of 5 stars
$1.01
-1.0%
$3.00
+197.0%
-36.3%$32.38M$1M-0.6617Short Interest ↑
News Coverage
CPIX
Cumberland Pharmaceuticals
0 of 5 stars
$2.13
-3.6%
N/A-6.6%$31.74M$42.01M-12.5385Upcoming Earnings
Analyst Report
Short Interest ↓
BFRG
Bullfrog AI
0 of 5 stars
$5.14
+12.0%
N/A+62.0%$31.30M$10,000.000.004Short Interest ↓
Positive News

Related Companies and Tools

This page (NASDAQ:KRRO) was last updated on 3/2/2024 by MarketBeat.com Staff